WFRF:(Henry Brian)
Sökning: WFRF:(Henry Brian) > (2005-2009) > A selective endothe...
- 1 av 4
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04239naa a2200385 4500 | |
| 001 | oai:DiVA.org:umu-41560 | |
| 003 | SwePub | |
| 008 | 110328s2009 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-415602 URI |
| 024 | 7 | a https://doi.org/10.1016/S0140-6736(09)61500-22 DOI |
| 040 | a (SwePub)umu | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Weber, Michael Au State University of New York, Downstate College of Medicine, New York, NY, USA4 aut |
| 245 | 1 0 | a A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension :b a randomised, double-blind, placebo-controlled trial |
| 264 | 1 | b Elsevier,c 2009 |
| 338 | a print2 rdacarrier | |
| 520 | a BackgroundHypertension cannot always be adequately controlled with available drugs. We investigated the blood-pressure-lowering effects of the new vasodilatory, selective endothelin type A antagonist, darusentan, in patients with treatment-resistant hypertension.MethodsThis randomised, double-blind study was undertaken in 117 sites in North and South America, Europe, New Zealand, and Australia. 379 patients with systolic blood pressure of 140 mm Hg or more (≥130 mm Hg if patient had diabetes or chronic kidney disease) who were receiving at least three blood-pressure-lowering drugs, including a diuretic, at full or maximum tolerated doses were randomly assigned to 14 weeks' treatment with placebo (n=132) or darusentan 50 mg (n=81), 100 mg (n=81), or 300 mg (n=85) taken once daily. Randomisation was made centrally via an automated telephone system, and patients and all investigators were masked to treatment assignments. The primary endpoints were changes in sitting systolic and diastolic blood pressures. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov, number NCT00330369.FindingsAll randomly assigned participants were analysed. The mean reductions in clinic systolic and diastolic blood pressures were 9/5 mm Hg (SD 14/8) with placebo, 17/10 mm Hg (15/9) with darusentan 50 mg, 18/10 mm Hg (16/9) with darusentan 100 mg, and 18/11 mm Hg (18/10) with darusentan 300 mg (p<0·0001 for all effects). The main adverse effects were related to fluid accumulation. Oedema or fluid retention occurred in 67 (27%) patients given darusentan compared with 19 (14%) given placebo. One patient in the placebo group died (sudden cardiac death), and five patients in the three darusentan dose groups combined had cardiac-related serious adverse events.InterpretationDarusentan provides additional reduction in blood pressure in patients who have not attained their treatment goals with three or more antihypertensive drugs. As with other vasodilatory drugs, fluid management with effective diuretic therapy might be needed. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Allmänmedicin0 (SwePub)302242 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex General Practice0 (SwePub)302242 hsv//eng |
| 700 | 1 | a Black, Henryu New York University, New York, NY, USA4 aut |
| 700 | 1 | a Bakris, Georgeu University of Chicago, Chicago, IL, USA4 aut |
| 700 | 1 | a Krum, Henryu Monash University, Clayton, VIC, Australia4 aut |
| 700 | 1 | a Linas, Stuartu Denver Health Medical Center, Denver, CO, USA4 aut |
| 700 | 1 | a Weiss, Robertu Maine Research Associates, Auburn, ME, USA4 aut |
| 700 | 1 | a Linseman, Jennifer Vu Gilead Sciences, Foster City, CA, USA4 aut |
| 700 | 1 | a Wiens, Brian Lu Gilead Sciences, Foster City, CA, USA4 aut |
| 700 | 1 | a Warren, Marshelle Su Gilead Sciences, Foster City, CA, USA4 aut |
| 700 | 1 | a Lindholm, Lars H.u Umeå universitet,Allmänmedicin,Umeå University Hospital, Umeå, Sweden4 aut0 (Swepub:umu)lali0003 |
| 710 | 2 | a State University of New York, Downstate College of Medicine, New York, NY, USAb New York University, New York, NY, USA4 org |
| 773 | 0 | t The Lancetd : Elsevierg 374:9699, s. 1423-1431q 374:9699<1423-1431x 0140-6736x 1474-547X |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-41560 |
| 856 | 4 8 | u https://doi.org/10.1016/S0140-6736(09)61500-2 |
- 1 av 4
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Weber, Michael A
- Black, Henry
- Bakris, George
- Krum, Henry
- Linas, Stuart
- Weiss, Robert
- visa fler...
- Linseman, Jennif ...
- Wiens, Brian L
- Warren, Marshell ...
- Lindholm, Lars H ...
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Allmänmedicin
- Artiklar i publikationen
- The Lancet
- Av lärosätet
- Umeå universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
